Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.58 |
| ▸ | CCR2 | P41597 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870954 | 0.86 | ROCK2 (0.65) | ROCK2ROCK1CCR2KDM4EALDH1A1 | |
| SCHEMBL658299 | 0.80 | ROCK2 (0.62) | ROCK2ROCK1CCR2CYP1A2CYP3A4 | |
| SCHEMBL12614692 | 0.79 | LTA4H (0.55) | L3MBTL1NPC1RAB9ATP53MEN1 | |
| SCHEMBL1089520 | 0.78 | CXCR4 (0.76) | HRH3L3MBTL1NPC1RAB9A | |
| SCHEMBL9194710 | 0.78 | SLC2A1 (0.65) | HRH3 | |
| SCHEMBL6153437 | 0.78 | ROCK2 (0.60) | ROCK2ROCK1CCR2ALDH1A1LTA4H | |
| SCHEMBL331018 | 0.78 | BCHE (0.68) | ROCK2ROCK1CCR2KDM4EALDH1A1 | |
| SCHEMBL331017 | 0.78 | BCHE (0.68) | ROCK2ROCK1CCR2KDM4EALDH1A1 | |
| SCHEMBL7811609 | 0.78 | NPC1 (0.78) | HRH3FAAHNPC1RAB9ATP53 | |
| Hydrochloric Acid SCHEMBL27903791 | 0.78 | LTA4H (0.54) | L3MBTL1NPC1RAB9ATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | disclosed |
| US-6251918-B1 | FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6251919-B1 | ADMINISTERING ANILINE DERIVATIVE FOR THERAPY OF PAIN | WARNER-LAMBERT | 2001-06-26 | — | — | US | disclosed |
| WO-1999043658-A1 | HETEROCYCLIC SUBSTITUTED ANILINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | ROCK2 1739/4885ROCK1 952/4885CCR2 2601/4885 |
| US-20030060632-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | ROCK2 1739/4885ROCK1 952/4885CCR2 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.